Bellwether Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.87M Buy
31,607
+8,890
+39% +$1.97M 1.16% 19
2025
Q4
$5.19M Buy
22,717
+64
+0.3% +$14.6K 0.83% 27
2025
Q3
$5.25M Buy
22,653
+18
+0.1% +$3.67K 0.87% 25
2025
Q2
$4.2M Buy
22,635
+102
+0.5% +$19K 0.72% 36
2025
Q1
$4.72M Hold
22,533
0.99% 24
2024
Q4
$4M Buy
22,533
+1,402
+7% +$258K 0.72% 28
2024
Q3
$4.17M Buy
21,131
+78
+0.4% +$14.6K 0.8% 29
2024
Q2
$3.61M Hold
21,053
0.76% 31
2024
Q1
$3.83M Hold
21,053
0.84% 30
2023
Q4
$3.26M Hold
21,053
0.8% 36
2023
Q3
$3.14M Sell
21,053
-145
-0.7% -$21.3K 0.85% 30
2023
Q2
$2.86M Buy
21,198
+145
+0.7% +$21.3K 0.84% 23
2023
Q1
$3.36M Hold
21,053
0.92% 21
2022
Q4
$3.4M Sell
21,053
-17
-0.1% -$2.61K 0.99% 18
2022
Q3
$2.83M Sell
21,070
-7
-0% -$1K 0.93% 26
2022
Q2
$3.23M Sell
21,077
-204
-1% -$31.2K 1.04% 23
2022
Q1
$3.45M Hold
21,281
1.03% 23
2021
Q4
$2.88M Sell
21,281
-9,000
-30% -$1.06M 0.9% 24
2021
Q3
$3.27M Buy
30,281
+281
+0.9% +$32.1K 1.09% 20
2021
Q2
$3.38M Hold
30,000
1.17% 21
2021
Q1
$3.25M Hold
30,000
1.29% 21
2020
Q4
$3.21M Buy
+30,000
New +$2.88M 1.41% 20

Other funds holding ABBV

Bellwether Advisors's ABBV Position: Q1 2026 in Review

Bellwether Advisors increased its AbbVie (ABBV) stake by 39% in Q1 2026, buying an estimated $1.97M and bringing the position to 31,607 shares worth $6.87M. The position accounts for 1.16% of the portfolio, ranked #19.

Bellwether Advisors first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Bellwether Advisors held 31,607 shares of AbbVie worth $6.87M as of Q1 2026.
  • Bellwether Advisors bought 8,890 AbbVie shares in Q1 2026, an estimated $1.97M.
  • AbbVie made up 1.16% of Bellwether Advisors's portfolio in Q1 2026, its #19 holding.
  • Bellwether Advisors first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Bellwether Advisors's 13F filing for Q1 2026, filed 12 May 2026.